Continuing Education Activity

Obesity, as defined by the World Health Organization (WHO), is characterized by the abnormal or excessive accumulation of fat that poses a health risk. This condition has been recognized since ancient times, with Hippocrates noting that obesity is not merely a disease but also a precursor to other health conditions. The most widely used measurement of obesity is the body mass index (BMI), introduced in 1972. However, other methods, such as waist-to-hip ratios, skin impedance, and dual x-ray absorptiometry, are also utilized. BMI has limitations, particularly in specific populations such as elite athletes and bodybuilders.

Prospective studies have produced inconsistent findings regarding the onset sequence between depression and obesity, emphasizing the need for an interprofessional approach. During hospital admissions, patients with obesity face increased risks of venous thromboembolism and wound infections, necessitating anticoagulation measures and infection control strategies to manage these risks effectively. Treatment involves pharmacological, surgical, dietary, and psychological interventions coordinated by an interprofessional team comprising primary care physicians, bariatric surgeons, specialist nurses, dieticians, behavioral health professionals, and exercise physiologists to develop personalized weight loss programs. This activity outlines the various comorbidities associated with obesity and underscores the crucial role of an interprofessional healthcare team in enhancing patient care through comprehensive management strategies.

Objectives:

• Identify the various comorbidities associated with obesity, including cardiovascular diseases, diabetes, depression, and venous thromboembolism.
• Assess the comorbidities associated with obesity to provide a medical management plan.
• Apply evidence-based guidelines for the prevention and management of obesity and its associated comorbidities.
• Collaborate with an interprofessional healthcare team to develop comprehensive care plans, monitor patient progress, and adjust treatment plans as needed.

Introduction

Obesity, as defined by the World Health Organization (WHO), is characterized by the abnormal or excessive accumulation of fat that poses a health risk. This condition has been recognized since ancient times, with Hippocrates noting that obesity is not merely a disease but also a precursor to other health conditions. The most widely used measurement of obesity is the body mass index (BMI), which was introduced in 1972 and has undergone minimal changes since then. However, other methods, such as waist-to-hip ratios, skin impedance, and dual x-ray absorptiometry, are also utilized.[1] 

The BMI numbers and classifications are listed below. However, individual variations exist, and BMI alone is insufficient to classify a person as obese or malnourished. BMI has limitations, particularly in specific populations such as elite athletes and bodybuilders, where increased muscle mass can falsely elevate BMI and not accurately reflect health status. In the pediatric population, BMI allows for comparison between children of the same sex and age. A BMI below the 5th percentile is considered underweight for children, while a BMI above the 95th percentile is considered obese. Please see StatPearls' companion resource, "BMI Classification Percentile And Cut Off Points," for further information.

Numbers and Classifications of Body Mass Index 

• Severely underweight individuals: BMI <16.5 kg/m²
• Underweight individuals: BMI <18.5 kg/m²
• Individuals with normal weight: BMI ≥18.5 to 24.9 kg/m²
• Individuals who are overweight: BMI ≥25 to 29.9 kg/m²
• Obesity: BMI ≥30 kg/m²

  • Obesity class I: BMI 30 to 34.9 kg/m²
  • Obesity class II: BMI 35 to 39.9 kg/m²
  • Obesity class III: BMI ≥40 kg/m² (also referred to as severe, extreme, or massive obesity)
• Asian and South Asian populations

  • Individuals who are overweight: BMI between 23 and 24.9 kg/m²
  • Obesity: BMI >25 kg/m²

Notably, different countries and ethnicities have different cutoffs for obesity, especially in Asia. For instance, Japan uses a BMI greater than 25 kg/m² as the cutoff for obesity.[2]

Obesity significantly impacts an individual's physical, mental, and social health. In addition, increased body weight has adverse effects on society through higher healthcare expenditures. Global obesity rates have seen a dramatic increase in the last decade, often described as a pandemic. The Centers for Disease Control and Prevention (CDC) reports that 42.4% of all adults in the United States experience obesity, and worldwide, obesity affects 650 million people. An urgent need exists for increased emphasis on health promotion and patient education to facilitate weight loss and prevent complications.

Function

The central control of hunger and hormonal regulation is critical in maintaining energy balance and regulating food intake. Various regions in the brain mediate hunger and satiety signals, responding to hormonal cues and nutrient availability. Hormones are key factors in this intricate system, signaling hunger or fullness and modulating metabolic processes to maintain equilibrium.

Central Control of Hunger

The primary center for hunger control is located within the hypothalamus, specifically in the arcuate nucleus, also known as the infundibular nucleus. The arcuate nucleus communicates with the brainstem and paraventricular nuclei, which relay pathways to the brainstem and limbic system. Together, they regulate metabolism and the emotional and behavioral changes associated with hunger and satiety.

Hormonal Control

Hormonal control plays a significant role in obesity. Hormones such as leptin, ghrelin, and insulin influence appetite regulation and metabolism. Imbalances in these hormones can lead to increased food intake and reduced energy expenditure, contributing to obesity.

Insulin: This is the primary hormone responsible for maintaining blood sugar homeostasis and regulating obesity.

• Insulin is secreted by the β-cells of the Islets of Langerhans in the pancreas in response to elevated blood sugar levels and other nutrients.

• In addition to its role in blood sugar regulation, insulin directly induces satiety. A study conducted in 1983 demonstrated that injecting insulin into the cerebral ventricles led to satiety. Further research revealed that insulin signaling receptors in the hypothalamus induce satiety and suppress hunger.[3][4][5]

Leptin: Leptin is produced by adipose tissue, and it primarily acts in the hypothalamus to decrease neuropeptide Y and downregulate hunger.

• Increased lipid levels in the blood stimulate the secretion of leptin. However, leptin levels are directly proportional to body adipose tissue.

• While meals trigger leptin secretion, the degree of stimulation is relative to total body adipose tissue. Hence, the suppression of hunger drive is present in individuals with normal or low body weight. However, this effect is less pronounced in individuals who are overweight or experience obesity due to chronically elevated leptin levels and hypothalamic desensitization. This is supported by studies where subjects with normal weight exposed to exogenous leptin experience weight loss—a response not typically observed in patients with obesity.[6][7][8][9]

Ghrelin: This peptide hormone is predominantly produced in the stomach and duodenum. 

• Ghrelin exhibits higher levels in the fasting state and spikes shortly before food ingestion, known as the cephalic response.

• Ghrelin acts within the hypothalamus by stimulating neuropeptide Y, which induces hunger and increases calorie intake. 

• Food ingestion downregulates ghrelin levels, with a more pronounced effect observed when consuming carbohydrates compared to protein and fat.[10]

Glucagon-Like Peptide-1

• Glucagon-like peptide-1 (GLP-1) is a hormone produced by L cells in the small intestine.

• GLP-1 is secreted in response to detecting nutrients in the intestinal lumen and released into the bloodstream.

• Within the hypothalamus, GLP-1 binds to the GLP-1 receptors, downregulating neuropeptide Y and hunger.[11]

Other polypeptides secreted in the gut, such as cholecystokinin (CCK), pancreatic polypeptide, and polypeptide YY, are known to increase satiety, although the mechanisms are not fully understood.

Issues of Concern

Obesity is a systemic issue that, as a result, affects multiple organ systems.

Cardiovascular System

Hypertension: Hypertension in patients with obesity involves complex mechanisms, including a combination of increased sympathetic activity and reduced parasympathetic activity. 

• Activation of the renin-angiotensin-aldosterone system (RAAS) changes the kidney. Certain ethnic groups have relatively low rates of hypertension, which is attributed to relatively decreased sympathetic activity. Furthermore, sympathetic blockade tends to lower blood pressure more effectively in patients with obesity.

• The sympathetic nervous system activates the RAAS system, leading to increased fluid and salt retention, and catecholamines can further enhance sympathetic activity. However, interestingly, adipocytes produce angiotensinogen and angiotensin 2 independently. Animal studies suggest that knockout genes for adipocyte angiotensinogen do not induce hypertension when animals consume obesogenic diets.

• Increased perinephric fat around the kidney can compress it, causing chronic inflammation, reduced blood flow, and enhanced sodium reabsorption in the medulla, thereby increasing salt retention. This sets off a self-perpetuating feedback loop through increased sodium levels, leading to further RAAS activation.[12][13][14][15][16]

Coronary artery disease: The development of coronary artery disease (CAD) is typically associated with diabetes, hypertension, dyslipidemia, and obstructive sleep apnea (OSA), which are known and frequent comorbidities of obesity. Whether obesity directly contributes to CAD is unclear and challenging to study in isolation due to the high prevalence of metabolic and respiratory conditions in patients with obesity. However, for each 5-unit increment of BMI, the risk of CAD increases by 30%.[17][18][19]

Heart failure: Obesity has been directly correlated with congestive heart failure with preserved ejection fraction (HFpEF). Although risk factors for congestive heart failure are prevalent in patients with obesity, the incidence rates are notably higher when risk-stratified for obesity alone.

The development of HFpEF is theorized to result from a combination of mechanisms. These include left ventricular hypertrophy due to increased cardiac output, which reduces myocardial function through lipotoxicity, systemic inflammation, and impaired protein function caused by increased glycosylation and collagen cross-links, ultimately leading to diastolic dysfunction. Additionally, increased epicardial fat and inflammation may further compound these effects.[20][21]

Atrial fibrillation: Atrial fibrillation is the most common cardiac arrhythmia associated with the development of heart failure and thromboembolism, potentially leading to strokes and life-threatening infarctions elsewhere in the body. Atrial fibrillation is prevalent in patients with obesity, as evidenced by the Framingham Heart Study, which identified a 5% increase in the risk of developing atrial fibrillation for each unit increase in BMI, particularly more than 30 kg/m².

The association between atrial fibrillation and obesity is hypothesized to result from the increase in cardiac output, leading to elevated pressures on the left side of the heart, particularly affecting the left atrium. This effect may be further exacerbated by diastolic dysfunction.[22][23][24]

Stroke: An increased risk of stroke exists with increasing BMI, including early-onset ischemic stroke. This correlation is further supported by a national survey study that identified patients with metabolically healthy obesity, who also face an increased risk, although less than those with metabolically unhealthy obesity and healthy individuals. The survey suggests that obesity independently serves as a risk factor for stroke development.[25][26]

Venous thromboembolism: Patients with obesity have reduced mobility, which increases the risk of venous thromboembolism (VTE). Increased abdominal pressure in obesity results in additional pressure on the iliac veins, leading to compression, reduced flow, and predisposition to chronic venous insufficiency. Obesity also contributes to a hypercoagulable state mediated by adipokines, which causes chronic inflammation and impaired fibrinolysis, leading to endothelial dysfunction and platelet activation. The risk of VTE in patients with obesity is up to 6 times higher than in those with normal BMI, with elevated rates of both deep vein thrombosis and pulmonary embolism.[27][28][29][30]

Respiratory System

Obstructive sleep apnea: OSA involves complete airway obstruction during sleep despite normal breathing efforts. This has widespread effects on the body, particularly negative cardiovascular and metabolic effects, likely mediated by systemic inflammation. These effects contribute to insulin resistance, dyslipidemia, hypertension, and CAD, with OSA independently increasing the risk for CAD.

As a recurring theme in obesity-related conditions, the cardiometabolic effects compound and significantly increase the risk of further negative consequences.[31]

Obesity hypoventilation syndrome: This condition is alternatively referred to as Pickwickian syndrome and is defined by 3 criteria in the absence of other causes—obesity, daytime hypercapnia, and sleep-disordered breathing.

• The development of obesity hypoventilation syndrome is complex but can be attributed to sleep-disordered breathing, which is often a manifestation of OSA, along with altered lung function and ventilatory control.

• During apneic periods, carbon dioxide accumulates, triggering an increased ventilatory response to clear the excess carbon dioxide. However, this regulatory mechanism is not observed in patients with obesity hypoventilation syndrome. The gradual buildup of carbon dioxide and adaptation by the body, such as increased bicarbonate retention by the kidneys and reduced central sensitivity to carbon dioxide for increasing ventilatory drive, leads to retention and results in daytime hypercapnia.

• Coupled with reduced respiratory muscle strength, increased abdominal splinting, and less effective breathing patterns in obesity, a significant ventilation/perfusion (V/Q) mismatch occurs.[32][33]

Endocrine System

Type 2 diabetes: Type 2 diabetes is a well-established association and complication of obesity, with around 80% of patients with type 2 diabetes being obese.

• The primary mechanism leading to the development of type 2 diabetes in patients with obesity is insulin resistance. Adipose tissue releases non-esterified fatty acids (NEFAs), which result in endothelial dysfunction, obesity-induced inflammation, and β-cell dysfunction.

• Insulin resistance has been strongly associated with elevated NEFAs. NEFAs are increased more in truncal obesity than in peripheral adipose tissue, suggesting increased lipolytic properties of abdominal-visceral fat.

• To further support the link between obesity and insulin resistance, losing just 5% of body weight during weight loss improves β-cell function and insulin sensitivity, with a steady correlation of improvement with increased weight loss.[34][35][36][37][38]

Dyslipidemia: Up to 70% of patients with obesity have comorbid dyslipidemia, seen clinically as elevated low-density lipoproteins (LDL) and reduced levels of high-density lipoproteins (HDL).

The pathophysiology is multifactorial and involves increased consumption and production of lipids and a reduced ability to break down and metabolize triglycerides.[39]

Metabolic syndrome: This constellation of clinical features includes truncal obesity, dyslipidemia, hypertension, and impaired fasting glucose. Up to 30% of patients with obesity are referred to as "metabolically healthy," as they lack these metabolic derangements. However, metabolic syndrome remains a significant risk factor for cardiovascular complications, particularly stroke.[40]

Vitamin D deficiency: Lower concentrations of vitamin D are well-documented in patients with obesity. This is thought to be secondary to vitamin D being fat-soluble and sequestered in the abundant adipose tissue of patients with obesity. However, lower levels of vitamin D have not demonstrated adverse effects on bone health, and vitamin D supplementation has not been shown to improve the metabolic state of obesity. Hence, the role of vitamin D in obesity remains inconclusive despite the well-documented association of low levels in patients with obesity.[41]

Nervous System 

Idiopathic intracranial hypertension: This condition is also referred to as benign intracranial hypertension or pseudotumor cerebri; the mechanism behind its development is unclear.

• As the name suggests, the condition causes symptoms of raised intracranial pressure, typically manifesting as severe headaches, which can be acute, chronic, or acute-on-chronic. Other symptoms include nausea, vomiting, and visual changes such as blurring or double vision.

• Elevated intracranial pressure results in pressure on the optic nerve, which may be seen as papilledema during fundoscopic examination. If the elevated intraocular pressure is sustained, this may result in vision loss. 

• This condition is not solely linked to obesity, as most individuals with obesity are unaffected and may have other risk factors such as the combined contraceptive pill or thyroid disease. However, idiopathic intracranial hypertension disproportionately affects patients with obesity, with 90% of cases occurring in those who are overweight or obese.

• The link is further supported by an increasing correlation with higher BMI, higher rates of induced vision loss, and disease remission in individuals who successfully lost between 6% and 10% of their weight.[42]

Musculoskeletal System

Osteoarthritis: The increased weight on the joints results in greater compressive forces and altered biomechanics.

• The knee is the most commonly affected joint, although the hand is at a higher risk despite not being a weight-bearing joint. This suggests a role for systemic inflammation in disease development. 

• Osteoarthritis can promote a vicious cycle, leading to a sedentary lifestyle that further contributes to weight gain.

• Surgical management is associated with an increased risk for complications, including prolonged hospital stays, infection, and the necessity for further surgery.

• Obesity-associated osteoarthritis has a significant economic burden, costing an estimated 89 billion USD per year. Moreover, significant indirect costs accrue from lost workdays and reduced productivity, which some have estimated to be roughly 4000 USD lost per person per year.[43][44]

Patients with obesity are more prone to experiencing falls and fractures in both children and adults. Additionally, conditions such as slipped upper femoral epiphyses and genu varus and valgus are more common among children with obesity.[45][46][47]

Gastrointestinal Tract

Nonalcoholic fatty liver disease: Nonalcoholic fatty liver disease (NAFLD) is currently the leading cause of chronic liver disease in both the United States and the United Kingdom, affecting approximately 30% of the population.

NAFLD is estimated to be the leading cause of liver transplantation by 2030 in the United States. The mechanisms underlying its development remain poorly understood but are closely linked to metabolic features associated with obesity. Please see StatPearls' companion resource, "Nonalcoholic Fatty Liver," for more information.

Gallstones: The positive correlation between increasing BMI and the development of gallstones is well-recognized. The risk increases even within the healthy weight range, indicating a strong link between weight gain and gallstones.

Gastroesophageal reflux disease: GERD is attributed to patients with obesity with nonspecific motility disorders within the esophagus, reduced lower esophageal tone, increased prevalence of hiatal hernias, and increased intra-abdominal pressures. As a result of acid reflux, patients with obesity are more likely to experience erosions, strictures, and pre-cancerous transformations, such as Barrett esophagus, as well as esophageal adenocarcinoma. Please see StatPearls' companion resource, "Gastroesophageal Reflux Disease (GERD)," for more information.[48][49]

Urinary Tract

The development of chronic kidney disease (CKD) is observed in patients with obesity, although the mechanism and risk factors are contentious. Prior studies have found conflicting evidence regarding the causal association between obesity and CKD. Systemic inflammation, increased oxidation, insulin resistance, and activation of the RAAS are proposed as potential mechanisms for developing CKD in obesity.[50][51]

Reproductive System

Due to peripheral aromatization of estrogens, increased androgens by insulin resistance, and decreased levels of sex-binding globulins, obesity leads to alterations in the hypothalamus-pituitary-ovarian axis. This results in potential disruptions to the female reproductive system, manifesting clinically as:

• Irregular menstrual cycles
• Ovulatory dysfunction and infertility
• Increased risk of miscarriage
• Endometrial hyperplasia and malignancy [52] 

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, irregular periods, and polycystic ovaries. PCOS can present many of the aforementioned reproductive physiological changes. The condition shares many features with obesity, affecting up to 88% of PCOS patients. The genetic predisposition for PCOS, through insulin resistance and increased steroid production, contributes to weight gain, with obesity as an independent risk factor. Urinary incontinence, especially stress incontinence, correlates strongly with increasing BMI, and weight loss proves effective as a treatment option.[53][54]

Obesity is also associated with sexual dysfunction in both women and men. Women with obesity often experience higher sexual dysfunction scores, which can significantly improve with weight loss interventions such as bariatric surgery. In men, obesity is an independent risk factor for developing erectile dysfunction, with 80% of those experiencing erectile issues having a BMI of 25 or greater.[55][56]

Psychiatric Disorders

The incidence of depression is higher in patients with obesity, especially among young women. Additionally, an association between obesity and dementia has been observed; however, the mechanism remains poorly understood, and whether obesity constitutes an independent risk factor for dementia is uncertain.[57][58][59][60]

Integumentary System

Obesity affects the skin in several ways by reducing skin hydration, decreasing collagen deposition relative to skin surface area, increasing sebum and sweat production, and altering circulation and lymphatics. Moreover, obesity increases the risk of infections, delays wound healing, and promotes the development of pressure sores. Additionally, elevated androgens and insulin resistance contribute to conditions such as hirsutism and acanthosis nigricans.[61]

Infections

Obesity is associated with higher rates of bacterial infections, post-surgical infections, and increased mortality from flu and COVID-19. Patients with obesity often require higher than typical doses of medications, which can lead to adverse outcomes. Notably, COVID-19 shows delayed viral shedding in individuals with obesity, although the rationale for extending the self-isolation period for these patients remains unclear.[62][63][64]

Neoplasm

The positive association between cancer and obesity is well-recognized. Proposed mechanisms include:

• Elevated growth factors and sex hormones.
• Adipocytokines such as leptin, adiponectin, and visfatin promote positive growth function and downregulate immunity and tumor regulation.
• Systemic inflammation.
• Altered gut microbiome.[65]

The risk of cancer is higher among women with obesity compared to men, and obesity increases the likelihood of cancer-related mortality. In the United States, obesity is attributed to 14% to 20% of cancer-related deaths in men and women, respectively.

Several well-associated cancers include:

• Esophageal adenocarcinoma
• Gastric cancer, particularly of the cardia
• Colorectal cancer
• Hepatocellular carcinoma
• Cholangiocarcinoma
• Pancreatic cancer
• Endometrial carcinoma
• Ovarian cancer
• Breast cancer
• Renal cell carcinoma
• Multiple myeloma [66][67][68][69][70]

Clinical Significance

Obesity is a prevalent comorbidity in medicine, posing a significant risk during hospital admissions, particularly for VTE. Therefore, an assessment is necessary, which typically involves administering anticoagulation injections and using anti-thromboembolic stockings. Another frequent issue is post-surgical wound infections, for which negative pressure wound dressings and stringent infection control during surgery are recommended.[71]

Other Issues

The probable association between obesity and depression has been extensively studied in scientific literature. Both conditions exhibit high prevalence rates and an increased risk of cardiovascular disease. While numerous cross-sectional studies have documented this relationship, its exact significance remains unclear.[72] Prospective studies have revealed inconsistent findings regarding the sequence in the onset of depression and obesity.[73] This discrepancy could be due to the methodological differences among studies, including variations in sample selection, follow-up duration, and/or the evaluation and diagnosis of depression and obesity.

The association between obesity and depression has also been examined in childhood and adolescence. A prospective study found that adolescent girls with obesity were up to 4 times more likely to develop major depression.[74] However, this risk was not significant for men. A meta-analysis of 8 longitudinal studies concluded that there is a bidirectional relationship between depression and obesity.[75] Thus, people with obesity had a 55% increased risk of developing depression over time, and individuals with depression had a 58% increased risk of obesity. Moreover, the relationship between obesity and depression showed a dose-response gradient, indicating a stronger association with higher levels of obesity.

Enhancing Healthcare Team Outcomes

Given the significant comorbidities associated with obesity, an emphasis on prevention is necessary to decrease the associated risks. While diet modification is straightforward, promoting weight loss through a comprehensive approach, including low-calorie diet plans, exercise regimens, and cognitive-behavioral therapy in psychotherapy, proves significantly more effective. An interprofessional healthcare team is optimal for supporting patients through pharmacological, surgical, dietary, and psychological interventions. Each specialty contributes evidence-based practices to develop personalized and effective weight loss programs. 

The ideal members of the interprofessional healthcare team include: 

• Primary care physician with expertise in obesity management
• Bariatric surgeon
• Specialist nurse
• Dietician
• Behavioral health professional
• Exercise physiologist [76][77]

Nursing, Allied Health, and Interprofessional Team Interventions

Obesity and its associated comorbidities present a significant health challenge. Nursing, allied health professionals, and interprofessional healthcare teams are crucial in addressing these issues. Below are key interventions they might undertake.

• Patient education and counseling: Nurses and allied health professionals can educate patients about the risks of obesity and associated comorbidities. This includes providing information on healthy eating, physical activity, and lifestyle modifications. Counseling helps patients set realistic goals and develop strategies for behavior change.
• Nutritional counseling: Registered dietitians and nutritionists collaborate with patients to create personalized meal plans to promote weight loss and manage comorbid conditions such as diabetes, hypertension, and hyperlipidemia. They provide guidance on portion control, reading food labels, and making healthy food choices.
• Exercise prescription and physical therapy: Allied health professionals, such as physiotherapists and exercise physiologists, specialize in designing exercise programs customized to the specific needs and abilities of patients with obesity and comorbidities. These programs typically incorporate aerobic exercises, strength training, and flexibility exercises to enhance overall fitness levels.
• Behavioral therapy: Psychologists and behavioral therapists play a crucial role in helping patients address psychological and emotional factors contributing to obesity, such as stress eating, emotional eating, and poor body image. They use cognitive behavioral therapy techniques to modify unhealthy thought patterns and behaviors related to food and exercise.
• Medication management: Nurses and advanced practice clinicians can assist in medication management for patients with obesity and the associated comorbidities. This may involve prescribing or adjusting medications for conditions such as diabetes, hypertension, dyslipidemia, and obesity (eg, weight loss medications).
• Interdisciplinary team collaboration: Interprofessional teams comprising physicians, nurses, dietitians, physical therapists, psychologists, and other allied health professionals collaborate to develop comprehensive care plans for patients with obesity and comorbidities. Frequent team meetings facilitate continuous assessment, care coordination, and the development of effective treatment strategies.
• Monitoring and follow-up: Healthcare professionals are crucial in monitoring patients' progress, including weight loss, improvements in comorbid conditions, and adherence to treatment plans. Follow-up appointments are essential for gathering patient feedback and evaluating clinical outcomes.

By implementing these interventions, nursing, allied health professionals, and interprofessional teams can effectively treat patients with obesity and associated comorbidities, thereby enhancing patients' health outcomes and quality of life.

Nursing, Allied Health, and Interprofessional Team Monitoring

Naturopathy in Obesity Management

Naturopathy, a form of complementary and alternative medicine, provides holistic approaches to managing obesity, often incorporating dietary supplements. Notably, it is crucial to approach all treatments, including naturopathic interventions, with caution and consideration.

Herbal supplements: Herbal supplements offer a natural approach to weight management, utilizing various plant-derived compounds with purported benefits, as mentioned below.

• Green tea extract: Green tea extract is derived from green tea leaves that are rich in catechins. Catechins are compounds known for their antioxidant properties, which may aid in weight management by boosting metabolism and promoting fat oxidation.

• Garcinia cambogia: Garcinia cambogia is extracted from a tropical fruit, which is reputed to suppress appetite and potentially inhibit fat production, although research findings are inconclusive.

• Forskolin: Forskolin is an herb from the mint family and is believed to increase the production of cyclic adenosine monophosphate, which may aid in fat breakdown and promote weight loss.

Fiber supplements: Fiber supplements that help in weight management are listed below. 

• Psyllium husk: Psyllium is a soluble fiber that can promote feelings of fullness, regulate bowel movements, and support healthy digestion, which may aid in weight management.

• Glucomannan: Glucomannan is a soluble fiber derived from the konjac root. This absorbs water in the digestive tract, creating a feeling of fullness and reducing calorie intake.

Probiotics: Probiotics are increasingly studied for their potential role in weight management.

• Certain strains of probiotics may help regulate gut microbiota composition, which could influence metabolic processes and inflammation related to obesity.

• Lactobacillus gasseri and L rhamnosus are among the strains studied for their potential benefits in weight management.

Mineral and vitamin supplements: Certain supplements, such as vitamin D and magnesium, aid in weight loss.

• Vitamin D: Low vitamin D levels have been associated with obesity, and supplementation may help improve insulin sensitivity and support weight loss.

• Magnesium: Magnesium deficiency has been linked to metabolic dysfunction, and supplementation may help improve insulin sensitivity and support weight management.

Omega-3 fatty acids: Fish oil supplements, rich in omega-3 fatty acids, may have anti-inflammatory effects, aid in weight loss, and reduce obesity-related complications.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Ghesmaty Sangachin M, Cavuoto LA, Wang Y. Use of various obesity measurement and classification methods in occupational safety and health research: a systematic review of the literature. BMC Obes. 2018;5:28. [PMC free article: PMC6211422] [PubMed: 30410773]

2.

Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet. 2005;94:1-12. [PubMed: 16145245]

3.

Woods SC, Porte D. The role of insulin as a satiety factor in the central nervous system. Adv Metab Disord. 1983;10:457-68. [PubMed: 6364721]

4.

Ahima RS, Antwi DA. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am. 2008 Dec;37(4):811-23. [PMC free article: PMC2710609] [PubMed: 19026933]

5.

Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol. 2003 Jan;24(1):1-10. [PubMed: 12609497]

6.

Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol. 2007 Sep 01;583(Pt 2):437-43. [PMC free article: PMC2277030] [PubMed: 17584844]

7.

Shetty GK, Matarese G, Magkos F, Moon HS, Liu X, Brennan AM, Mylvaganam G, Sykoutri D, Depaoli AM, Mantzoros CS. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011 Aug;165(2):249-54. [PMC free article: PMC3159386] [PubMed: 21602313]

8.

Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, Gong H, Arampatzi K, Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6585-90. [PMC free article: PMC3080974] [PubMed: 21464293]

9.

Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013 Jul 02;18(1):29-42. [PubMed: 23770129]

10.

Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature. 2001 Jan 11;409(6817):194-8. [PubMed: 11196643]

11.

Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab. 2013 Feb;24(2):85-91. [PMC free article: PMC3594872] [PubMed: 23332584]

12.

Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006 Nov;48(5):787-96. [PubMed: 17000932]

13.

Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension. 2000 Oct;36(4):531-7. [PubMed: 11040231]

14.

Wofford MR, Anderson DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001 Jul;14(7 Pt 1):694-8. [PubMed: 11465655]

15.

Schütten MT, Houben AJ, de Leeuw PW, Stehouwer CD. The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension. Physiology (Bethesda). 2017 May;32(3):197-209. [PubMed: 28404736]

16.

Yiannikouris F, Karounos M, Charnigo R, English VL, Rateri DL, Daugherty A, Cassis LA. Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15;302(2):R244-51. [PMC free article: PMC3349391] [PubMed: 22071160]

17.

Dwyer TM, Banks SA, Alonso-Galicia M, Cockrell K, Carroll JF, Bigler SA, Hall JE. Distribution of renal medullary hyaluronan in lean and obese rabbits. Kidney Int. 2000 Aug;58(2):721-9. [PubMed: 10916095]

18.

Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010 May;33(5):386-93. [PubMed: 20442753]

19.

Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, van Dam RM, Hu FB, Visscher TL, Menotti A, Thorpe RJ, Jamrozik K, Calling S, Strand BH, Shipley MJ., BMI-CHD Collaboration Investigators. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007 Sep 10;167(16):1720-8. [PubMed: 17846390]

20.

Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 01;347(5):305-13. [PubMed: 12151467]

21.

Karason K, Jamaly S. Heart failure development in obesity: mechanistic pathways. Eur Heart J. 2020 Sep 21;41(36):3485. [PubMed: 32556158]

22.

Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1565-72. [PubMed: 26371114]

23.

Munger TM, Dong YX, Masaki M, Oh JK, Mankad SV, Borlaug BA, Asirvatham SJ, Shen WK, Lee HC, Bielinski SJ, Hodge DO, Herges RM, Buescher TL, Wu JH, Ma C, Zhang Y, Chen PS, Packer DL, Cha YM. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. J Am Coll Cardiol. 2012 Aug 28;60(9):851-60. [PubMed: 22726633]

24.

Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol. 2011 Mar 22;57(12):1368-74. [PMC free article: PMC3077126] [PubMed: 21414533]

25.

Mitchell AB, Cole JW, McArdle PF, Cheng YC, Ryan KA, Sparks MJ, Mitchell BD, Kittner SJ. Obesity increases risk of ischemic stroke in young adults. Stroke. 2015 Jun;46(6):1690-2. [PMC free article: PMC4458137] [PubMed: 25944320]

26.

Zhang N, Liang G, Liu M, Zheng G, Yu H, Shi Y, Zhang Y, Wang H, Li Y, Xu Y, Lu J. Metabolically healthy obesity increases the prevalence of stroke in adults aged 40 years or older: Result from the China National Stroke Screening survey. Prev Med. 2021 Jul;148:106551. [PubMed: 33862034]

27.

Raju S, Darcey R, Neglén P. Iliac-caval stenting in the obese. J Vasc Surg. 2009 Nov;50(5):1114-20. [PubMed: 19878789]

28.

Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013 Sep;20(5):437-44. [PMC free article: PMC4445633] [PubMed: 23817170]

29.

Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: A review. Open J Prev Med. 2012 Nov;2(4):499-509. [PMC free article: PMC4520798] [PubMed: 26236563]

30.

Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005 Sep;118(9):978-80. [PubMed: 16164883]

31.

Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010 Mar;137(3):711-9. [PMC free article: PMC3021364] [PubMed: 20202954]

32.

Liu C, Chen MS, Yu H. The relationship between obstructive sleep apnea and obesity hypoventilation syndrome: a systematic review and meta-analysis. Oncotarget. 2017 Nov 03;8(54):93168-93178. [PMC free article: PMC5696252] [PubMed: 29190986]

33.

Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999: diabetes and obesity. Diabetes Care. 2000 Jan;23(1):118-24. [PubMed: 10857981]

34.

Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. Biochem Soc Trans. 2008 Jun;36(Pt 3):348-52. [PubMed: 18481955]

35.

Mukherjee B, Hossain CM, Mondal L, Paul P, Ghosh MK. Obesity and insulin resistance: an abridged molecular correlation. Lipid Insights. 2013;6:1-11. [PMC free article: PMC4147781] [PubMed: 25278764]

36.

Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996 Jun 15;97(12):2859-65. [PMC free article: PMC507380] [PubMed: 8675698]

37.

Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587-91. [PMC free article: PMC4259868] [PubMed: 25506234]

38.

Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, de las Fuentes L, He S, Okunade AL, Patterson BW, Klein S. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016 Apr 12;23(4):591-601. [PMC free article: PMC4833627] [PubMed: 26916363]

39.

Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013 Apr 12;5(4):1218-40. [PMC free article: PMC3705344] [PubMed: 23584084]

40.

Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17. [PubMed: 28585193]

41.

Vranić L, Mikolašević I, Milić S. Vitamin D Deficiency: Consequence or Cause of Obesity? Medicina (Kaunas). 2019 Aug 28;55(9) [PMC free article: PMC6780345] [PubMed: 31466220]

42.

Subramaniam S, Fletcher WA. Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review. J Neuroophthalmol. 2017 Jun;37(2):197-205. [PubMed: 27636748]

43.

Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. Maturitas. 2016 Jul;89:22-8. [PubMed: 27180156]

44.

Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009 Sep;15(8 Suppl):S230-5. [PubMed: 19817509]

45.

Kim SJ, Ahn J, Kim HK, Kim JH. Obese children experience more extremity fractures than nonobese children and are significantly more likely to die from traumatic injuries. Acta Paediatr. 2016 Oct;105(10):1152-7. [PubMed: 27634684]

46.

Premaor MO, Comim FV, Compston JE. Obesity and fractures. Arq Bras Endocrinol Metabol. 2014 Jul;58(5):470-7. [PubMed: 25166037]

47.

Nowicki P, Kemppainen J, Maskill L, Cassidy J. The Role of Obesity in Pediatric Orthopedics. J Am Acad Orthop Surg Glob Res Rev. 2019 May;3(5):e036. [PMC free article: PMC6553626] [PubMed: 31321371]

48.

Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol. 2015 Sep;30(9):1009-19. [PubMed: 26374741]

49.

Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014 Mar;43(1):161-73. [PMC free article: PMC3920303] [PubMed: 24503366]

50.

Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2005 Oct;46(4):587-94. [PubMed: 16183412]

51.

Kovesdy CP, Furth SL, Zoccali C., World Kidney Day Steering Committee. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Can J Kidney Health Dis. 2017;4:2054358117698669. [PMC free article: PMC5433675] [PubMed: 28540059]

52.

Silvestris E, de Pergola G, Rosania R, Loverro G. Obesity as disruptor of the female fertility. Reprod Biol Endocrinol. 2018 Mar 09;16(1):22. [PMC free article: PMC5845358] [PubMed: 29523133]

53.

Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. [PMC free article: PMC6734597] [PubMed: 31523137]

54.

Subak LL, Richter HE, Hunskaar S. Obesity and urinary incontinence: epidemiology and clinical research update. J Urol. 2009 Dec;182(6 Suppl):S2-7. [PMC free article: PMC2866035] [PubMed: 19846133]

55.

Bond DS, Wing RR, Vithiananthan S, Sax HC, Roye GD, Ryder BA, Pohl D, Giovanni J. Significant resolution of female sexual dysfunction after bariatric surgery. Surg Obes Relat Dis. 2011 Jan-Feb;7(1):1-7. [PMC free article: PMC2974005] [PubMed: 20678969]

56.

Skrypnik D, Bogdański P, Musialik K. [Obesity--significant risk factor for erectile dysfunction in men]. Pol Merkur Lekarski. 2014 Feb;36(212):137-41. [PubMed: 24720114]

57.

Gibson-Smith D, Bot M, Snijder M, Nicolaou M, Derks EM, Stronks K, Brouwer IA, Visser M, Penninx BWJH. The relation between obesity and depressed mood in a multi-ethnic population. The HELIUS study. Soc Psychiatry Psychiatr Epidemiol. 2018 Jun;53(6):629-638. [PMC free article: PMC5959973] [PubMed: 29644388]

58.

Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med. 2003 Sep 22;163(17):2058-65. [PubMed: 14504119]

59.

Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005 Jun 11;330(7504):1360. [PMC free article: PMC558283] [PubMed: 15863436]

60.

Albanese E, Davis B, Jonsson PV, Chang M, Aspelund T, Garcia M, Harris T, Gudnason V, Launer LJ. Overweight and Obesity in Midlife and Brain Structure and Dementia 26 Years Later: The AGES-Reykjavik Study. Am J Epidemiol. 2015 May 01;181(9):672-9. [PMC free article: PMC4408946] [PubMed: 25810457]

61.

Hirt PA, Castillo DE, Yosipovitch G, Keri JE. Skin changes in the obese patient. J Am Acad Dermatol. 2019 Nov;81(5):1037-1057. [PubMed: 31610857]

62.

Wang Y, Chen Y. Increased Risk of Bacterial Infections among the Obese with Chronic Diseases. J Nutr Health Aging. 2015 May;19(5):595-600. [PubMed: 25923492]

63.

Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. 2020 Jun;57(6):759-764. [PMC free article: PMC7130453] [PubMed: 32249357]

64.

Thelwall S, Harrington P, Sheridan E, Lamagni T. Impact of obesity on the risk of wound infection following surgery: results from a nationwide prospective multicentre cohort study in England. Clin Microbiol Infect. 2015 Nov;21(11):1008.e1-8. [PubMed: 26197212]

65.

Berger NA. Obesity and cancer pathogenesis. Ann N Y Acad Sci. 2014 Apr;1311:57-76. [PMC free article: PMC4500037] [PubMed: 24725147]

66.

Steele CB, Thomas CC, Henley SJ, Massetti GM, Galuska DA, Agurs-Collins T, Puckett M, Richardson LC. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2017 Oct 03;66(39):1052-1058. [PMC free article: PMC5720881] [PubMed: 28981482]

67.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-38. [PubMed: 12711737]

68.

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K., International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. N Engl J Med. 2016 Aug 25;375(8):794-8. [PMC free article: PMC6754861] [PubMed: 27557308]

69.

Cao Z, Zheng X, Yang H, Li S, Xu F, Yang X, Wang Y. Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study. Br J Cancer. 2020 Oct;123(8):1336-1344. [PMC free article: PMC7555864] [PubMed: 32728095]

70.

Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. Post Reprod Health. 2017 Dec;23(4):183-198. [PubMed: 28720017]

71.

Peterson AT, Bakaysa SL, Driscoll JM, Kalyanaraman R, House MD. Randomized controlled trial of single-use negative-pressure wound therapy dressings in morbidly obese patients undergoing cesarean delivery. Am J Obstet Gynecol MFM. 2021 Sep;3(5):100410. [PubMed: 34058423]

72.

Blasco BV, García-Jiménez J, Bodoano I, Gutiérrez-Rojas L. Obesity and Depression: Its Prevalence and Influence as a Prognostic Factor: A Systematic Review. Psychiatry Investig. 2020 Aug;17(8):715-724. [PMC free article: PMC7449839] [PubMed: 32777922]

73.

Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev. 2011 May;12(5):e438-53. [PubMed: 21414128]

74.

Anderson SE, Cohen P, Naumova EN, Jacques PF, Must A. Adolescent obesity and risk for subsequent major depressive disorder and anxiety disorder: prospective evidence. Psychosom Med. 2007 Nov;69(8):740-7. [PubMed: 17942847]

75.

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010 Mar;67(3):220-9. [PubMed: 20194822]

76.

Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Serdula M, Brown TJ, Schmid CH, Lau J. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med. 2004 Nov 15;117(10):762-74. [PubMed: 15541326]

77.

Foster D, Sanchez-Collins S, Cheskin LJ. Multidisciplinary Team-Based Obesity Treatment in Patients With Diabetes: Current Practices and the State of the Science. Diabetes Spectr. 2017 Nov;30(4):244-249. [PMC free article: PMC5687103] [PubMed: 29151714]

Disclosure: Yizhe Lim declares no relevant financial relationships with ineligible companies.

Disclosure: Joshua Boster declares no relevant financial relationships with ineligible companies.